WebDoctor Encyclopedia

Gastrointestinal

GIST & neuroendocrine

Encyclopedia entries in GIST & neuroendocrine.

  1. GIST & neuroendocrine

    Appendiceal neoplasms

    Appendiceal neoplasms are rare tumours of the appendix, from LAMN to adenocarcinoma and goblet-cell adenocarcinoma. This entry covers rupture risk and CRS/HIPEC.

    4,845 words
  2. GIST & neuroendocrine

    GI neuroendocrine tumours

    GI neuroendocrine tumours arise from gut neuroendocrine cells. This entry covers grade, somatostatin analogues, and peptide receptor radionuclide therapy.

    4,130 words
  3. Colorectum

    Pseudomyxoma peritonei (PMP)

    Pseudomyxoma peritonei (PMP) is a rare condition in which jelly-like mucus from a burst appendix tumour builds up inside the abdomen. Most cases are low grade and can be cured with cytoreductive surgery and heated chemotherapy (HIPEC).

    2,076 words

Part 1: Gastrointestinal Stromal Tumors (GIST)

1. Definition & Origin

  • Cell of Origin: Interstitial Cells of Cajal (ICCs) — the “pacemaker cells” of the GI tract responsible for peristalsis (gut motility), or their stem cell precursors.
  • Classification: The most common mesenchymal neoplasm of the GI tract (distinct from carcinomas, which are epithelial). Classified as a Soft Tissue Sarcoma.

2. Molecular Pathogenesis (The Defining Feature)

>85% of GISTs are driven by gain-of-function mutations in receptor tyrosine kinases.

Gene Frequency Exon/Location Clinical Significance
KIT ~75–80% Exon 11 (most common), 9, 13, 17 Standard TKI sensitive (Imatinib). Exon 9 needs higher dose. Exon 17 = resistance.
PDGFRA ~5–10% Exon 18 (D842V mutation most common) D842V is resistant to Imatinib. Requires Avapritinib.
Wild Type (WT) ~10–15% SDH deficiency, NF1, BRAF, NTRK fusions Pediatric/Young adult GIST; Syndromic (Carney Triad/Stratakis); Require specific targeted agents (e.g., NTRK inhibitors).

3. Epidemiology & Site

  • Incidence: ~4,000–6,000 cases/year (USA).
  • Median Age: 60–65 years.
  • Primary Sites: Stomach (60%), Small Intestine (30–35%), Rectum (5%), Esophagus (<1%), Mesentery/Omentum (rare, “Extra-gastrointestinal GIST”).

4. Clinical Presentation

  • Asymptomatic: Incidental finding on imaging/endoscopy (increasingly common).
  • Symptomatic: GI bleeding (hematemesis, melena, anemia — most common), abdominal pain, palpable mass, early satiety, obstruction, perforation (rare).
  • Paraneoplastic: Hypoglycemia (rare, due to IGF-2 secretion).

5. Diagnosis & Pathology

  • Immunohistochemistry (IHC):
    • CD117 (c-KIT): Positive in ~95% (Gold standard).
    • DOG1: Positive in ~98% (More sensitive/specific; positive in KIT-negative GISTs).
    • CD34: ~70% positive.
    • Desmin / S100 / SMA: Usually Negative (helps rule out leiomyoma, schwannoma).
  • Molecular Testing (Mandatory): KIT/PDGFRA genotyping required before starting systemic therapy to guide drug selection.

6. Risk Stratification (Prognosis)

Used for localized disease post-resection to determine need for adjuvant therapy.

  • Modified NIH Criteria (Fletcher/Miettinen): Based on Tumor Size and Mitotic Count (per 5 mm²).
  • AFIP / Miettinen Criteria: Adds Anatomic Site (Gastric vs. Non-gastric have better prognosis for same size/mitoses).
  • Tumor Rupture: Upstages to High Risk / Stage IV (peritoneal contamination).

7. Staging (AJCC 8th Ed / TNM)

  • Based on Size, Mitotic Rate, Site, and Metastasis.
  • No formal “Stage Grouping” for survival curves in AJCC 8th; uses Risk Categories.

8. Treatment Algorithm

A. Localized Disease (Resectable)

  • Surgery: En bloc R0 resection (negative margins). Lymphadenectomy NOT required (GISTs rarely metastasize to lymph nodes; hematogenous spread to liver/peritoneum).
  • Laparoscopic vs. Open: Laparoscopic acceptable for tumors <5 cm (avoid rupture).
  • Adjuvant Imatinib (3 years standard):
    • High Risk: 3 years standard; consider 5 years (SSGXVIII/AIO trial showed 5yr OS benefit).
    • Intermediate Risk: Individualized (often 1–3 years).
    • Low/Very Low Risk: Observation.
  • Neoadjuvant Imatinib: For borderline resectable, large tumors, or to preserve organ function (sphincter). Typical duration: 6–12 months pre-op.

B. Metastatic / Unresectable Disease

  • First Line: Imatinib 400 mg/day (Standard). 800 mg/day for KIT Exon 9 mutation.
  • Response Assessment: CT scan at 2–3 months. CHOI Criteria or PERCIST (PET-CT) preferred over RECIST (GISTs often necrose/cystically degenerate without shrinking).
  • Progression on Imatinib:
    1. Sunitinib (2nd Line): 50 mg 4/2 schedule. Benefit in KIT Exon 9, WT.
    2. Regorafenib (3rd Line): 160 mg 3 weeks on/1 week off.
    3. Ripretinib (4th Line+): Broad KIT switch-control inhibitor. Standard 4th line.
    4. Avapritinib: Specific for PDGFRA Exon 18 (D842V) — 1st line standard for this mutation. Not for standard KIT-mutant GIST (toxicity/cognitive effects).
    5. NTRK Inhibitors (Larotrectinib/Entrectinib): For NTRK fusion+ GIST (rare).
  • Surgery in Metastatic Setting: “Debulking” or metastasectomy considered only for oligoprogression on TKI (stable disease elsewhere) or symptomatic relief. Multidisciplinary decision.

9. Follow-up

  • CT Abdomen/Pelvis: Every 3–6 months for 5 years, then annually (liver/peritoneum most common recurrence sites).
  • PET-CT: For equivocal CT findings or early response assessment.

Part 2: Neuroendocrine Tumors (NETs) — Gastroenteropancreatic (GEP-NETs)

1. Definition & Origin

  • Cell of Origin: Neuroendocrine cells (diffuse neuroendocrine system) — amine precursor uptake and decarboxylation (APUD) cells. Share features of neurons (synaptophysin, chromogranin) and endocrine cells (hormone secretion).
  • Classification: Epithelial neoplasms (Carcinomas).
  • Terminology Shift: “Carcinoid” is outdated but still used for well-differentiated NETs of GI tract/lungs. Preferred: Well-differentiated NET (Grade 1/2) vs. Poorly differentiated Neuroendocrine Carcinoma (NEC, Grade 3).

2. Classification & Grading (WHO 2019 / WHO 2022 Digestive Systems)

Critical Distinction: Differentiation + Grade (Ki-67 / Mitotic Count)

Category Differentiation Grade Ki-67 Index Mitoses (per 2mm²/10 HPF) Behavior
NET G1 Well-differentiated Low < 3% < 2 Indolent
NET G2 Well-differentiated Intermediate 3–20% 2–20 Moderate
NET G3 Well-differentiated High > 20% > 20 Aggressive but may retain hormone expression/SSTR positivity
NEC G3 (Small/Large Cell) Poorly differentiated High > 20% (usually 50–100%) > 20 Very Aggressive (Cisplatin/Etoposide chemo sensitive)
MiNEN Mixed Neuroendocrine-Non-neuroendocrine Neoplasm Both components ≥30% Graded separately Treat per aggressive component

3. Functional vs. Non-Functional

  • Functional (Syndromic): Secrete bioactive peptides causing clinical syndromes.
    • Carcinoid Syndrome: Serotonin → Flushing, Diarrhea, Valvular Heart Disease (Right sided), Bronchospasm. (Midgut NETs + Liver Mets).
    • Insulinoma: Hypoglycemia (Pancreas).
    • Gastrinoma (Zollinger-Ellison): Ulcers, Diarrhea (Duodenum/Pancreas).
    • Glucagonoma, VIPoma, Somatostatinoma: Rare.
  • Non-Functional: Majority (esp. Pancreatic NETs). Present via mass effect or metastatic burden.

4. Primary Sites & Epidemiology

  • Incidence: Rising sharply (better detection). ~170,000 patients living in US.
  • Common Sites: Small Intestine (Ileum – “Midgut”), Lung, Rectum, Pancreas, Appendix, Stomach, Colon.
  • Hereditary Syndromes: MEN1 (Pancreatic NETs, Parathyroid, Pituitary), VHL (Pancreatic NETs), NF1 (Duodenal Somatostatinoma), TSC (Pancreatic NETs).

5. Diagnosis & Workup

  1. Biochemistry:
    • Chromogranin A (CgA): General marker (↑ in renal failure, PPI use — false +).
    • Specific Hormones: Insulin, Gastrin, Glucagon, VIP, PP, Serotonin (5-HIAA urine).
    • 24-hr Urine 5-HIAA: Gold standard for Carcinoid Syndrome (dietary restrictions needed).
  2. Cross-sectional Imaging: Multiphasic CT (Arterial phase critical for hypervascular NETs) or MRI Liver (gold standard for liver mets).
  3. Functional Imaging (Somatostatin Receptor Imaging):
    • Ga-68 DOTATATE PET/CT: Gold Standard. High sensitivity for SSTR2+ tumors (Well-diff NETs).
    • FDG PET/CT: Essential for High Grade (G3/NEC) or dedifferentiated tumors (Warburg effect). Discordance (High FDG / Low DOTATATE) = Poor prognosis.
  4. Endoscopy: EUS (Pancreas/Rectum/Stomach), Colonoscopy (Ileal/Rectal), Capsule Endoscopy (Occult Small Bowel).
  5. Pathology: Ki-67 index is mandatory. IHC: Synaptophysin, Chromogranin A, CD56, SSTR2a. Ki-67 must be assessed in highest proliferative area (hotspot).

6. Staging (AJCC 8th Ed / ENETS TNM)

  • Site-specific staging systems (e.g., Pancreas, Stomach, Small Intestine, Appendix differ).
  • General: T (Size/Invasion), N (Nodes), M (Mets).
  • Stage IV: Distant mets (Liver #1, Bone, Lung, Peritoneum).

7. Treatment Algorithm (Multidisciplinary Tumor Board Mandatory)

A. Localized Disease (Stage I–III)

  • Surgery = Curative Intent.
    • Small Bowel (Midgut): Resection + Mesenteric Lymphadenectomy (nodes almost always involved). Avoid “blind” resection; map mesentery.
    • Pancreas: Enucleation (small, non-functional, away from duct) vs. Formal Resection (Whipple, Distal Pancreatectomy). Lymphadenectomy standard.
    • Stomach/Rectum: Endoscopic resection (EMR/ESD) for small (<1cm), G1, no deep invasion, no nodes (Rectal NETs <1cm G1: endoscopic ok). Else formal surgery + nodes.
    • Appendix: <1cm, G1, margins neg, no nodes → Appendectomy. >2cm or high risk features → Right Hemicolectomy. 1–2cm: Controversial (consider nodes, LVI, margin).
  • Adjuvant Therapy: No standard adjuvant chemo/TKI. Observation standard. Exception: Pancreatic NET G2/G3 with high risk features (R1, Node+), clinical trial or consider capecitabine/temozolomide (CAPTEM) based on extrapolated data.

B. Metastatic Disease (Stage IV) — “Chronic Management”

Line / Scenario Well-Differentiated (NET G1/G2/G3) Poorly Differentiated (NEC G3)
Symptom Control (Carcinoid Syndrome) Somatostatin Analogs (SSA): Octreotide LAR / Lanreotide Depot. Telotristat Ethyl (tryptophan hydroxylase inhibitor) for refractory diarrhea. Not applicable (rarely functional).
1st Line Antitumor (Low Tumor Burden / Slow Growth) Watch & Wait (asymptomatic, low volume, indolent). Platinum/Etoposide (Cisplatin/Carboplatin + Etoposide) — Urgent start.
1st Line Antitumor (Progressive / High Burden) SSA (PROMID/CLARINET trials): PFS benefit (esp. Midgut, Ki-67 <10%).
PRRT (Lu-177 DOTATATE): NETTER-1 trial. Standard for SSTR+, progressive Midgut NETs (G1/G2). Increasingly used earlier/pancreatic.
CAPTEM: Preferred for Pancreatic NETs (high response rate).
Everolimus (RADIANT-3/4): mTOR inhibitor. PFS benefit (Pancreas, Lung, GI).
Sunitinib (RADIANT-3): VEGFR inhibitor. Approved for pNET only.
N/A
Subsequent Lines Sequence: PRRT → CAPTEM → Everolimus → Sunitinib (pNET) → Chemo (Streptozocin/5-FU or Temozolomide based).
Surgery/Locoregional: Liver-directed (Resection, Ablation, TAE/TACE/TARE/SIRT) for oligometastatic liver disease.
2nd Line: Temozolomide/Capecitabine, Topotecan, Amrubicin, Immunotherapy (low evidence).
High Grade NET G3 (Well-Diff) Treat like NET G2 (SSA, PRRT, CAPTEM, Everolimus) — Avoid Platinum/Etoposide (less effective than in NEC). Treat as NEC (Platinum/Etoposide).

C. Special Scenarios

  • Insulinoma: Surgery curative. Medical: Diazoxide, Everolimus, SSA (caution: can worsen hypoglycemia).
  • Gastrinoma: High-dose PPI + Surgery (curative if localized). MEN1: Controversial surgery timing (often wait for >2cm primary).
  • Carcinoid Heart Disease: Echocardiography screening (5-HIAA >300). Valve replacement often needed. SSA/PrRT may stabilize.
  • Bone Mets: Bisphosphonates / Denosumab + PRRT / EBRT.

Part 3: Head-to-Head Comparison Summary

Feature GIST Neuroendocrine Tumors (NETs)
Lineage Mesenchymal (Sarcoma) Epithelial (Carcinoma)
Cell of Origin Interstitial Cells of Cajal (ICC) Diffuse Neuroendocrine System (APUD)
Key Driver Mutation KIT (80%), PDGFRA (10%), SDH/BRAF/NTRK MEN1, DAXX/ATRX, mTOR pathway, RB1/TP53 (NEC)
Diagnostic IHC CD117 (c-KIT), DOG1 Synaptophysin, Chromogranin A, Ki-67, SSTR2a
Grading Risk Stratification (Size + Mitoses + Site) WHO Grade (Ki-67 / Mitoses) + Differentiation
Lymph Node Mets Very Rare (Hematogenous spread) Common (Lymphatic spread standard)
Primary Systemic Tx Tyrosine Kinase Inhibitors (TKIs): Imatinib → Sunitinib → Regorafenib → Ripretinib Somatostatin Analogs (SSA), PRRT (Lu-177), mTOR/VEGF inhibitors, Chemo (CAPTEM, Platinum/Etoposide)
Role of Surgery (Mets) Oligoprogression on TKI / Symptom control Aggressive: Resection, Ablation, Liver-directed therapies (TARE/TACE) standard for liver-dominant mets
Functional Imaging FDG PET/CT (High avidity) Ga-68 DOTATATE PET/CT (SSTR imaging); FDG for High Grade
Hereditary Syndromes Carney Triad, Carney-Stratakis, NF1 MEN1, VHL, NF1, TSC
Prognosis (Metastatic) Median OS ~5+ years (TKI era) Highly variable: Indolent (Midgut G1: 10+ yrs) to Aggressive (NEC: months)

Key Clinical Pearls for the Practitioner

  1. Don’t confuse “Spindle Cell” morphology:
    • GIST = CD117+/DOG1+ / Synaptophysin-.
    • NET = Synaptophysin+/Chromogranin+ / CD117-.
    • Rare overlap: Paraganglioma (S100+ sustentacular cells), but distinct clinical context.
  2. Biopsy before Treatment: Never start Imatinib or SSA/PRRT without tissue diagnosis (except rare unresectable hepatic mets with classic imaging + biochemical profile).
  3. Ki-67 is King in NETs: A “NET G3” (Well-diff, Ki-67 25%) behaves differently and gets different drugs than an “NEC G3” (Poorly diff, Ki-67 80%). Always verify differentiation status.
  4. GIST Mutation Testing is Actionable:
    • PDGFRA D842V → Avapritinib (1st line). Do not give Imatinib.
    • KIT Exon 9 → Imatinib 800mg.
    • SDH-deficient / WT → Imatinib less effective; consider clinical trials / Sunitinib earlier.
  5. PRRT Eligibility: Requires SSTR-positivity on Ga-68 DOTATATE PET (Krenning Score 3/4) and adequate renal function/hematologic reserve. Not for NEC (usually SSTR negative).
  6. Surveillance Differs:
    • GIST: CT Abdomen/Pelvis (Liver/Peritoneum focus).
    • NETs: Multiphasic CT or MRI Liver + Ga-68 DOTATATE PET (Whole body) + Chromogranin A / 5-HIAA.
  7. Carcinoid Crisis: Risk during surgery/anesthesia/embolization for functional NETs. Prophylaxis: Octreotide IV bolus + infusion peri-procedurally.

Disclaimer: This summary is for educational purposes. Oncology guidelines (NCCN, ESMO, ENETS, NANETS) update rapidly. Always refer to current guidelines and discuss cases in a multidisciplinary tumor board.